Silvano has been with us as a venture partner since 2018. He is the founder and chairman of the board of BiovelocITA, the first Italian biotech accelerator, which was founded by Sofinnova Partners.
Silvano is also the founder of EOS S.p.A. (Ethical Oncology Science), a Sofinnova Capital V portfolio company created in 2006. He served as chief executive of EOS until the company was acquired by Clovis Oncology, Inc. in 2013.
Silvano co-founded and served as CEO of Novuspharma, a portfolio company of Sofinnova Capital III. In 2000, the company went public on the Italian market Nuovo Mercato, raising over €160 million. Novuspharma was acquired by Cell Therapeutics, Inc. (CTI) in 2003. Sofinnova Partners was the lead investor in all these initiatives.
Previously, Silvano was the Head of R&D at Boehringer Mannheim Italy. He holds a degree in organic chemistry from the University of Pisa.